Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients
Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients
Not yet recruiting · NCT07620561 · Registry updated 2026-09-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients | Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, dermatitis, prurigo, skin disorder | Not yet recruiting | Phase 2 | 2026-09-03 | NCT07620561 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eli Lilly and Company | 370 |
| University of Maryland, Baltimore | 198 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UM Dermatology at UM Professional Building | Baltimore | United States | 1 |